search
Across the pharmaceutical industry, digital connectivity is reshaping how therapies are developed, manufactured, and delivered. As pipelines grow more complex and timelines compress, companies are increasingly relying on CDMO pharma partners that can integrate data, systems, and workflows across development and manufacturing. Digitally connected operations are no longer a future ambition; they are becoming a prerequisite for efficient, resilient CDMO drug development.
Feb 09, 2026
Peptide-based therapeutics are increasingly critical in modern drug development. Positioned between small molecules and biologics, peptides offer strong target specificity, favorable safety profiles, and wide therapeutic potential. As more peptide candidates advance from discovery to clinical and commercial stages, the ability to develop and manufacture peptide APIs efficiently, at scale, and with consistent quality has become essential.
Feb 06, 2026
Antibody-drug conjugates (ADCs) represent a cutting-edge approach to targeted therapy, uniting the precision of antibodies with the powerful effects of cytotoxic drugs. As these sophisticated molecules become increasingly important in oncology and other therapeutic fields, their development depends on advanced analytical expertise. ADC pharma programs are highly complex, requiring meticulous characterization, stringent quality control, and comprehensive bioanalytical services to ensure success.
Feb 03, 2026
Speed, efficiency, and smart use of limited materials are constant pressures in early drug development. High-throughput experimentation (HTE) has emerged as a powerful way for drug developers to address these challenges by rapidly exploring reaction conditions and generating actionable data that supports downstream scale-up.
Jan 30, 2026
Supply chain resilience has become both a competitive advantage and a responsibility in pharmaceutical manufacturing. Over the past two decades, China has grown into a dominant force in the global supply chain, accounting for a significant share of active pharmaceutical ingredient (API) intermediates and raw materials.
Jan 28, 2026
